close
NEW: LANDSCAPE IN GENE THERAPY COMPANIES 2019
©National-Institutes-of-Health-NIH-via-VisualHunt
Analyzes

NEW: LANDSCAPE IN GENE THERAPY COMPANIES 2019

 

©National-Institutes-of-Health-NIH-via-VisualHunt

BioPharmAnalyses and OctopusyX BioConsulting are proud to announce the launch of their up-dated and enriched 2019 edition of their report entitled “Landscape… in Gene Therapy Companies”.  This report provides you with an in-depth analysis of more than 230 companies involved in this expanding field. (UPDATED SEP 2019)

 

In this 800-pages report, a must-have read one, you will find included:

More than 230 closely scrutinized companies
More than 600 products identified
including more than 200 products at the clinical stage
A Product Breakdown by Development Phase
More than 300 VC or investors mentioned
More than 250 pathologies referred.

 A Detailed Overview of Companies Involved in:

AAV-based Gene Therapy
LV-based Gene Therapy
RNA-based Derived Drugs (RNAi, mRNA Therapeutics…)
Gene Editing Therapy
CDMO (Contract, Development and Manufacturing Organisation)
Miscellaneous (Including Hubs and Non Viral Gene Transfer)*

Each Technical Datasheet includes for Every Company:

– General Informations (location, website, FTE, management with e-mail contacts)
– Core Business in Gene Therapy
– Financial Data (stock informations, market cap, financial highlights, recent fundings….)
– Pipeline (discovery, pre-clinical, phase I / II / III, marketed products)
– Orphan Drug Designations
– Clinical Trials
– Latest Developments in Gene Therapy
– Latest Publications 

* CAR-T strategies will be dealt separately in the updated edition of our briefing on CAR-T clinical trials. The 2019 edition will be published next November.

Please click here to get  sample pages of Landscape in Gene Therapy Companies 2019
Please click here to get the Order Form for Landscape in Genetherapy companies 2019


COMMENTS ARE OFF THIS POST